EFFECTS OF THE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST DUP 753 ON BLOOD-PRESSURE AND RENAL FUNCTIONS IN SPONTANEOUSLY HYPERTENSIVE PH DOGS

被引:57
作者
BOVEE, KC [1 ]
WONG, PC [1 ]
TIMMERMANS, PBMWM [1 ]
THOOLEN, MJMC [1 ]
机构
[1] UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104
关键词
ANGIOTENSIN-II RECEPTOR ANTAGONISTS; DUP; 753; CANINE GENETIC HYPERTENSION; BLOOD PRESSURE; RENAL FUNCTION;
D O I
10.1093/ajh/4.4.327S
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
A colony of genetic hypertensive dogs with systolic blood pressure of 140 to 220 mm Hg and diastolic blood pressure > 100 mm Hg in the trained state was used. The objective of this study was to investigate the hemodynamic and renal effects of the novel angiotensin II receptor antagonist DuP 753 given intravenously to these dogs. Renal functions and blood pressure were measured 45 to 75 min after the intravenous administration of DuP 753 at 1, 3, 10, and 30 mg/kg and were compared to control (placebo) treatment. Arterial pressure was slightly but significantly and dose-dependently reduced by DuP 753. Glomerular filtration rate increased significantly in a dose-dependent manner. Similarly, effective renal plasma flow was dose-dependently increased. Filtration fraction was unchanged. Renal vascular resistance was significantly reduced in a dose-dependent manner at 3, 10, and 30 mg/kg of DuP 753. DuP 753 increased fractional sodium excretion at all doses and increased fractional potassium excretion only at the highest doses. The vasopressor effects of angiotensin I and II were dose-dependently inhibited by DuP 753. These data show that DuP 753 has beneficial renal hemodynamic effects and lowers arterial pressure in this canine model of essential hypertension.
引用
收藏
页码:S327 / S333
页数:7
相关论文
共 37 条
[1]  
Hollenberg N.K., Pharmacologie interruption of the renin-angiotensin system, Ann Rev Pharmacol Toxicol, 19, pp. 559-582, (1979)
[2]  
Laragh J.H., Endocrine mechanisms in congestive cardiac failure renin, aldosterone and atrial natriuretic hormone, Drugs, 5, pp. 1-12, (1986)
[3]  
Sweet C.S., Blaine E.H., Angiotensin converting enzyme inhibitors, Pharmacology of Antihypertensive Drugs, pp. 343-363, (1984)
[4]  
Gomez H.J., Cirillo V.J., Irvin J.D., Enalapril: A review of human pharmacology, Drugs, 30, 1, pp. 13-24, (1985)
[5]  
Soffer R.L., Sen I., Angiotensin receptor is a desirable locus for physiological specific inhibition of the renin-angiotensin system, J Cardiovasc Pharmacol, 7, 4, pp. S69-S72, (1985)
[6]  
Douglas J.G., Angiotensin receptor subtypes of the kidney cortex, Am J Physiol, 253, pp. F1-F7, (1987)
[7]  
Uva B., Vallarino M., Ghiani P., Heterogeneity of angiotensin II receptors in membranes of developing rat metanephrons, Cell Biochem Funct, 3, pp. 273-276, (1985)
[8]  
Chiu A.T., Herblin W.F., McCall D.E., Et al., Identification of angiotensin II receptor subtypes, Biochem Biophys Res Commun, 165, pp. 196-203, (1989)
[9]  
Whitebread S., Mele M., Kamber B., De Gasparo M., Preliminary biochemical characterization of two angiotensin II receptor subtypes, Biochem Biophys Res Commun, 163, pp. 284-291, (1990)
[10]  
Chang R., Lotti V.J., T wo distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands, Mol Pharmacol, 29, pp. 347-351, (1990)